DATASET
Figure S1.xlsx (41.07 kB)
DATASET
Figure S2.xlsx (13.79 kB)
DATASET
Figure S3.xlsx (24.27 kB)
DATASET
Figure S4.xlsx (26.54 kB)
DATASET
Figure S5.xlsx (34.79 kB)
DATASET
Figure S6.xlsx (29.33 kB)
DATASET
Figure S7.xlsx (30.99 kB)
DATASET
Figure 1.xlsx (30.79 kB)
DATASET
Figure 2.xlsx (34.9 kB)
DATASET
Figure 3.xlsx (35.26 kB)
DATASET
Figure 4.xlsx (23.67 kB)
DATASET
Figure 5.xlsx (48.76 kB)
DATASET
Figure 6.xlsx (17.44 kB)
1/0
Commensal bacteria augment Staphylococcus aureus infection by inactivation of phagocyte-derived reactive oxygen species
dataset
posted on 2021-08-10, 09:39 authored by Josie F. Gibson, Grace Pidwill, Oliver T. Carnell, Bas G. J. Surewaard, Daria Shamarina, Joshua A. F. Sutton, Charlotte Jeffery, Aurélie Derré-Bobillot, Cristel Archambaud, Matthew K Siggins, Eric J. G. Pollitt, Simon A. Johnston, Pascale Serror, Shiranee Sriskandan, Stephen A. Renshaw, Simon J. FosterStaphylococcus aureus is a human commensal organism and opportunist pathogen, causing
potentially fatal disease. The presence of non-pathogenic microflora or their components,
at the point of infection, dramatically increases S. aureus pathogenicity,
a process termed augmentation. Augmentation is associated with macrophage
interaction but by a hitherto unknown mechanism. Here, we demonstrate a breadth
of cross-kingdom microorganisms can augment S. aureus disease and that
pathogenesis of Enterococcus faecalis can also be augmented.
Co-administration of augmenting material also forms an efficacious vaccine model
for S. aureus. In vitro, augmenting material protects S.
aureus directly from reactive oxygen species (ROS), which correlates
with in vivo studies where augmentation restores full virulence to the ROS-susceptible,
attenuated mutant katA ahpC. At the cellular level, augmentation increases
bacterial survival within macrophages via amelioration of ROS, leading to proliferation
and escape. We have defined the molecular basis for augmentation that represents
an important aspect of the initiation of infection.
Animal work in the UK was performed in accordance with the Animal (Scientific Procedures) Act 1986. At the University of Sheffield, work was completed under project licences P3BFD6DB9 and PPL 40/3699 for murine work, or P1A4A7A5E for zebrafish work, with ethical approval from the University of Sheffield Local Ethical Review Panel. At Imperial College London, work was conducted under licence P4C824899 with approval from the Imperial ethical review board. At INRAE, animal work was approved by the local ethics committee (COMETHEA or “Comité d’Ethique en Expérimentation Animale”, Centre de Recherche Ile de France - Jouy en Josas – Antony) under the registration numbers 15_08, and by the French Ministry of Higher Education and Research APAFIS #480-2015041518048149v1, where all animal experiments were performed in accordance with European directive 2010/63/EU. Animal experiments in Calgary were approved by the University of Calgary Animal Care Committee and were in compliance with the Canadian Council for Animal Care Guidelines (protocol nr. AC16-0148). MDMs were derived, with informed consent, from the blood of healthy volunteers, in accordance with guidelines from the South Sheffield Research Ethics Committee (07/Q2305/7).
Funding
MR/R001111/1
MR/J009156/1
MR/L008610/1
History
Ethics
- The project has ethical approval and have included the number in the description field
Policy
- The data complies with the institution and funders' policies on access and sharing
Sharing and access restrictions
- The data can be shared openly
Data description
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files
